Skip to main content

Table 1 Baseline demographics of treatment-naïve patients

From: Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study

Characteristic

Treatment-naïve

(N = 39)

Mean (SD) age, years

68.4 (12.6)

 Range

39–88

Sex, n (%)

 

 Female

21 (53.8)

 Male

18 (46.2)

Race/Ethnicity, n (%)

 

 White

20 (51.3)

 Black, Asian, or other

3 (7.7)

 Not recorded in chart

16 (41.0)

Diagnosis, n (%)

 

 BRVO

18 (46.2)

 CRVO

21 (53.8)

Mean (SD) duration of macular edema, months

4.9 (16.7)

 Median

1.2

 Range

0 to 105

Prior treatment for complications of retinal vein occlusion, n (%)

0 (0)

Glaucoma or ocular hypertension at baseline, n (%)

 

 Yes

6 (15.4)

 No

23 (59.0)

 Not recorded in chart

10 (25.6)

Using IOP-lowering medication at baseline, n (%)

3 (7.7)

History of IOP response to steroid, n (%)

 

 Yes

1 (2.6)

 No

24 (61.5)

 Not recorded in chart

14 (35.9)

Lens status, n (%)

 

 Phakic

23 (59.0)

 Pseudophakic

15 (38.5)

 Not recorded

1 (2.6)

Mean (SD) BCVA, lines

8.5 (5.1)

 Snellen

20/125

Mean (SD) central retinal thickness, μm

550 (207)

  1. BCVA best-corrected visual acuity, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, IOP intraocular pressure, SD standard deviation, VEGF vascular endothelial growth factor